Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-blinded, Vehicle-controlled Trial to Investigate the Efficacy and Safety of Twice Daily Delgocitinib Cream in Adult Participants With Lichen Sclerosus During a 12-Week Initial Treatment Period Followed by a 40-Week Continuation Treatment Period

NCT07335588 is registered in ClinicalTrials.gov with LEO Pharma as lead sponsor.

NCT NCT07335588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07335588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-blinded, Vehicle-controlled Trial to Investigate the Efficacy and Safety of Twice Daily Delgocitinib Cream in Adult Participants With Lichen Sclerosus During a 12-Week Initial Treatment Period Followed by a 40-Week Continuation Treatment Period
Lead sponsor
LEO Pharma
Phase
Phase 3
Overall status
Recruiting
Start date
May 1, 2026
Completion date
December 29, 2028
Enrollment
652 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

lichen sclerosus